The E3 Ubiquitin Protein Ligase XIAP pipeline drugs market research report outlays comprehensive information on the E3 Ubiquitin Protein Ligase XIAP targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the E3 Ubiquitin Protein Ligase XIAP pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology which include the indications Oncology, and Hypopharyngeal Cancer. It also reviews key players involved in E3 Ubiquitin Protein Ligase XIAP targeted therapeutics development with respective active and dormant or discontinued products.
The E3 Ubiquitin Protein Ligase XIAP pipeline targets constitutes close to seven molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, IND/ CTA Filed, and Preclinical stages are 1, 2, 1, and 1 respectively. Similarly, the universities portfolio in Discovery comprises 2 molecule.
E3 Ubiquitin Protein Ligase XIAP overview
E3 Ubiquitin-Protein Ligase X-linked inhibitor of apoptosis protein (XIAP) also known as inhibitor of apoptosis protein 3 (IAP3) and baculoviral IAP repeat-containing protein 4 (BIRC4) is a protein that stops apoptotic cell death. It modulates inflammatory signaling and immunity, copper homeostasis, mitogenic kinase signaling, cell proliferation, as well as cell invasion and metastasis. It acts as a direct caspase inhibitor. Directly bind to the active site pocket of CASP3 and CASP7 and obstructs substrate entry. It inactivates CASP9 by keeping it in inactive state. It regulates the BMP signaling pathway and the SMAD and MAP3K7/TAK1 dependent pathways leading to NF-kappa-B and JNK activation. It acts as an important regulator of innate immune signaling via regulation of Nodlike receptors (NLRs).
For a complete picture of E3 Ubiquitin Protein Ligase XIAP’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
